Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction

Lancet

Volumn 350, Issue 9075, 1997, Pages 389-396

  Fuster, Valentin ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

EID: 0030837662     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)01180-X     Document Type: Article

References (32)

1. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974; i: 436-40.
2. The Coronary Drug Project Research Group. Aspirin in coronary heart disease. Circulation 1980; 62: V59-62.
3. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Circulation 1980; 62: V53-58.
4. Breddin K, Loew D, Oberla K, Walter E. The German-Austrian aspirin trial: a comparison of acetyl salicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980; 62: V63-72.
5. Anon. Aspirin after myocardial infarction. Lancet 1980; i: 1172-73.
6. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study, part II: secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
8. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
10. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
11. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
12. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points, analysis from the ATACS trial. Circulation 1994; 89: 81-88.
13. Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127-29.
14. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-31.
15. Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 1995; 75: 23B-26B.
16. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.
17. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-79.
18. Salomaa VV, Rasi VP, Vahtera EM, et al. Haemostatic factors and lipoprotein (a) in three geographic areas in Finland: the Finrisk Haemostasis Study. J Cardiovasc Risk 1994; 1: 241-48.
19. Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne W. Randomised controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988; 9: 836-43.
20. Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 1995; 75: 23B-26B.
21. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardivascular disease. Circulation 1993; 83: 659-75.
22. Goodman SG, Langer A, Durica SS, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Am J Cardiol 1994; 657-61.
23. Vorchheimer DA, Fuster V. Coumadin aspirin reinfarction study: rationale and design. J Thromb Thrombol 1995; 2: 171-76.
24. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
26. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63 (abstr).
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56 (abstr).
28. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99: 746-51.
29. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-29.
30. Cowburn P, Cleland JGF. SPAF-III results. Eur Heart J 1996; 17: 1129.
31. Ferguson JJ. Meeting highlights: American College of Cardiology 45th annual scientific session, Orlando, Florida, March 24 to 27, 1996. Circulation 1996; 94: 1-9.
32. Meade TW. Oral anticoagulants in the secondary and primary prevention of myocardial infarction and coronary death. In: Poller L, Hirsh J, eds. Oral Anticoagulants. New York: Oxford University Press, 1996: 130-42.